This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

In recent years, the incidence of non-viral hepatocellular carcinoma (HCC) has increased
dramatically, which is probably related to the increased prevalence of metabolic syndrome …

Obesity is a global epidemic and overwhelming evidence indicates that it is a risk factor for
numerous cancers, including hepatocellular carcinoma (HCC), the third leading cause of …

Hepatocellular carcinoma has a substantial global mortality burden which is rising despite
advancements in tackling the traditional viral risk factors. Metabolic (dysfunction) associated …

SGLT2i reduces risk of developing HCC in patients with co-ex... : Hepatology SGLT2i reduces
risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A …

The incidence of diabetes mellitus and hepatocellular carcinoma (HCC) has been
increasing worldwide during the last few decades, in the context of an increasing prevalence …

Obesity and diabetes are risk factors for hepatocellular carcinoma (HCC); however, the
underlying mechanisms are yet to be elucidated. Adeno‐associated virus (AAV) frequently …

Background To assess the association of cirrhosis and hepatocellular carcinoma (HCC) with
the use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) versus long‐acting …

Hepatocellular carcinoma (HCC) is a common complication in patients with chronic liver
disease and leads to significant morbidity and mortality. Liver disease and liver cancer are …

Metabolic dysfunction-associated steatotic liver disease (MASLD) closely associates with
obesity and type 2 diabetes. Lifestyle intervention and bariatric surgery aiming at substantial …